Researchers discover unexpected role of an immune system receptor; blocking it halts human cancer cell growth and improves survival in animal models
For some cancers, initial treatment with chemotherapy brings positive, but only temporary, results: tumors shrink, but then rebound as the cancer becomes drug-resistant. This pattern of remission-resistance-relapse is particularly true for pancreatic cancer, an aggressive disease in which early success is often countered by eventual disease progression.
To wit: The one-year relative survival rate for pancreatic cancer is 20 percent, according to the American Cancer Society. The five-year rate is just 7 percent.
The reason: Current multidrug chemotherapy regimens targeting pancreatic cancer typically do not fully eradicate all cancer cells, leaving behind drug-resistant cells that harbor aberrant stem cell properties and can drive tumor regrowth and metastasis.
In a new paper publishing in the April 4, 2019 online issue of Cell, an international team of scientists led by researchers at University of California San Diego School of Medicine employed an array of next-generation sequencing and gene-editing tools, such as CRISPR, to map the molecular dependencies —and thus vulnerabilities — of pancreatic cancer stem cells.
Most notably, they found that a key hormone receptor called retinoic acid receptor-related orphan receptor gamma or ROR?, previously studied in inflammation and T-cell differentiation, was especially active during pancreatic cancer progression, and that blocking it markedly slowed patient derived tumor growth and improved survival in animal models.
“These studies revealed an unexpected role for immuno-regulatory genes in the maintenance of the most aggressive, drug-resistant cells in pancreatic cancer,” said senior study author Tannishtha Reya, PhD, UC San Diego professor in the departments of Pharmacology and Medicine. In particular, ROR? emerged as a key regulator. ROR? rose with cancer progression and its inhibition through genetic and pharmacological approaches resulted in a striking defect in pancreatic cancer growth.
“Our work shows that immune system signals are hijacked by pancreatic cancer, and suggests that therapies currently being tested for autoimmune indications should be considered for testing in pancreatic cancer,” said Reya.
Using genome scale approaches to map stem cell dependencies in pancreatic cancer “will be invaluable for understanding the basis of therapy resistance and recurrence and for discovering new vulnerabilities in pancreatic cancer,” said Reya. “Beyond providing new scientific insight, this work can help identify pathways for which clinical grade inhibitors may already exist and can thus be rapidly tested in pancreatic cancer.”
In particular, she said the discovery of ROR?‘s role in promoting tumor growth provides a new avenue for research and potential therapies. “One exciting aspect is the possibility that nuclear hormone receptors could represent therapeutic targets for pancreatic cancer. In fact, drugs targeting ROR? have already been developed by several pharmaceutical companies, and are in trials for autoimmune diseases. Our findings suggest that these agents could also be a valuable therapeutic strategy for pancreatic cancer.”
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- Capital Health Earns National Honor for Excellence in Treating Pancreatic Canceron February 24, 2021 at 10:14 am
The National Pancreas Foundation (NPF) recently recognized Capital Health Cancer Center as an NPF Center for treating pancreatic cancer. After a rigorous audit, Capital Health earned this designation ...
- Pancreatic cancer research walk in Boca Raton goes virtual this yearon February 24, 2021 at 7:45 am
Lace up your sneakers and hit the pavement for the Lustgarten Foundation's annual pancreatic Cancer research walk/run in Boca Raton. The event takes place Feb. 28 and is virtual this year because of ...
- AIM ImmunoTech’s Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Canceron February 24, 2021 at 6:18 am
Prof. Casper van Eijck, surgeon and a global leading expert in pancreatic cancer Prof. Casper van Eijck, surgeon and a global leading expert in pancreatic cancer Kazem Kazempour, Ph.D., CEO and ...
- Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9on February 24, 2021 at 6:09 am
Alterations in glycosylation in tumours facilitate tumour progression. Here, the authors show that pancreatic ductal adenocarcinomas present increased sialylation, which stimulates the polarisation of ...
- Pancreatic Cancer Market Research Revealing the Growth Rate and Business Opportunities to 2027on February 23, 2021 at 11:49 am
The Global Pancreatic Cancer Market is expected to exceed more than US$ 13 billion by 2024. The Global Pancreatic ...
- Cancer Death Rates Continue to Fall in Europe, Except For...on February 23, 2021 at 6:34 am
Cancer death rates overall continue to fall in the EU, with the exception of pancreatic cancer in both sexes and lung cancer among women.
- Improved pentamethine cyanine nanosensors for optoacoustic imaging of pancreatic canceron February 23, 2021 at 5:35 am
Optoacoustic imaging is a new biomedical imaging technology with clear benefits over traditional optical imaging and ultrasound. While the imaging technology has improved since its initial development ...
- AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in pancreatic canceron February 22, 2021 at 11:11 pm
Stock quotes by finanzen.net PRESS RELEASE NEW INDEPENDENT PUBLICATION IN THE PEER ...
- Cancer in Context: Rise of GI Caseson February 22, 2021 at 4:00 pm
John Whyte, MD, chief medical officer at WebMD, and medical oncologist Timothy Cannon, MD, discuss the rise of gastrointestinal cancers from your esophagus to your colon. Is there a link to red meat ...
- Investment needed to bring down pancreatic cancer death rates in Europeon February 21, 2021 at 11:50 pm
Researchers have called on European policymakers to make adequate resources available to tackle pancreatic cancer, a disease that is almost invariably fatal and where little progress has been made ...
via Bing News